John Stalfort, III Biography and Net Worth

Director of Acumen Pharmaceuticals

Mr. John Stalfort, III is the Director of Acumen Pharmaceuticals.

What is John A. Stalfort, III's net worth?: The estimated net worth of John A. Stalfort, III is at least $1.19 million as of August 16th, 2023. Mr. Stalfort, III owns 999,381 shares of Acumen Pharmaceuticals stock worth more than $1,189,263 as of March 30th. This net worth evaluation does not reflect any other investments that Mr. Stalfort, III may own. Learn More about John A. Stalfort, III's net worth.
How do I contact John A. Stalfort, III?: The corporate mailing address for Mr. Stalfort, III and other Acumen Pharmaceuticals executives is , , . Acumen Pharmaceuticals can also be reached via phone at 434-297-1000 and via email at investors@acumenpharm.com. Learn More on John A. Stalfort, III's contact information.
Has John A. Stalfort, III been buying or selling shares of Acumen Pharmaceuticals?: John A. Stalfort, III has not been actively trading shares of Acumen Pharmaceuticals over the course of the past ninety days. Most recently, on Tuesday, July 6th, John A. Stalfort III bought 35,000 shares of Acumen Pharmaceuticals stock. The stock was acquired at an average cost of $16.00 per share, with a total value of $560,000.00. Learn More on John A. Stalfort, III's trading history.
Who are Acumen Pharmaceuticals' active insiders?: Acumen Pharmaceuticals' insider roster includes Marc Benioff (CEO), Nathan Fountain (Director), Paul Manning (Director), and John Stalfort, III (Director). Learn More on Acumen Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Acumen Pharmaceuticals?: During the last year, insiders at the sold shares 9 times. They sold a total of 131,526 shares worth more than $233,123.83. The most recent insider tranaction occured on January, 23rd when CFO Matt Zuga sold 28,902 shares worth more than $49,711.44. Insiders at Acumen Pharmaceuticals own 7.1% of the company. Learn More about insider trades at Acumen Pharmaceuticals.
Information on this page was last updated on 1/23/2025.

John A. Stalfort, III Insider Trading History at Acumen Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/6/2021	Buy	35,000	$16.00	$560,000.00

John A. Stalfort, III Buying and Selling Activity at Acumen Pharmaceuticals

Acumen Pharmaceuticals Company Overview

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Today's Range

Now: $1.19

$1.15

$1.25

50 Day Range

MA: $1.38

$1.15

$1.75

2 Week Range

Now: $1.19

$1.10

$4.06

Volume

118,755 shs

Average Volume

288,822 shs

Market Capitalization

$71.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.02